Thursday May 25th 2017

Archive for January, 2015

Mechanisms of immunological tolerance in central nervous system inflammatory demyelination

Mechanisms of immunological tolerance in central nervous system inflammatory demyelination

Original link –  Mechanisms of immunological tolerance in central nervous system inflammatory demyelination [Read More]

Features of Hydrolysis of Specific and Nonspecific Globular Proteins and Oligopeptides by Antibodies against Viral Integrase from Blood of…

Features of Hydrolysis of Specific and Nonspecific Globular Proteins and Oligopeptides by Antibodies against Viral Integrase from Blood of…

Authors: Odintsova ES, Dmitrenok PS, Baranova SV, Timofeeva AM, Buneva VN, Nevinsky GA Abstract It was shown previously that, as differentiated from canonical proteases, abzymes against myelin basic protein (MBP) from blood of patients with multiple sclerosis and systemic [Read More]

Persistent Headache in Patients With Multiple Sclerosis Starting Treatment With Fingolimod

Persistent Headache in Patients With Multiple Sclerosis Starting Treatment With Fingolimod

(Source: Headache: The Journal of Head and Face Pain) [Read More]

 Page 1 of 110  1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]